New Targeted Therapy Adds Benefit to Erlotinib in Some Patients with Advanced Lung Cancer, Sarah Cannon Research Institute Study

EurekAlert! -- A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.